Security Snapshot

Spyre Therapeutics, Inc. - Common Stock, $0.0001 par value (SYRE) Institutional Ownership

CUSIP: 00773J202

13F Institutional Holders and Ownership History from Q3 2023 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

212

Shares (Excl. Options)

69.06MFull value: 69,055,502 · shares · 30 Sep 2026

Price

$89.03

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0.01%
Share change
+3,934,767
Value change
+$349,330,169
Number of holders
212
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
101,961,572
SEC-reported price per share
$98.96
Insider filing price
$98.96
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • SYRE - Spyre Therapeutics, Inc. - Common Stock, $0.0001 par value is tracked under CUSIP 00773J202.
  • 212 institutions reported positions in Q3 2026.
  • 7 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 264 to 212 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $8.52BFull value: $8,518,140,426 · USD · 30 Jun 2026
    to
    $6.17BFull value: $6,170,449,278 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 212 institutions filings for Q3 2026.

Open SEC evidence

Security key

00773J202

13F reference period

Q3 2026

13F holders

212

13D/G owners

7

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
7
Security
SYRE
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Fairmount Funds Management LLC 10% 0% $906,856,108 +$46,185,203 10,185,961 +5.4% Harwin Peter Evan 07 Oct 2026
Paradigm Biocapital Advisors LP 5.1% $403,844,970 4,457,450 Paradigm BioCapital Advisors LP 24 Sep 2026
PERCEPTIVE ADVISORS LLC 4.9% -2% $383,312,075 4,319,496 0% Perceptive Advisors LLC 30 Jun 2026
RTW INVESTMENTS, LP 4.8% -23% $377,322,125 +$55,906,200 4,251,996 +17% RTW Investments, LP 30 Jun 2026
BlackRock, Inc. 6.6% $59,323,024 3,962,635 BlackRock, Inc. 30 Jun 2025
Venrock Healthcare Capital Partners III, L.P. 4.6% $40,335,429 2,685,448 Venrock Healthcare Capital Partners III, L.P. 31 Dec 2024
TANG CAPITAL MANAGEMENT LLC 2.4% -58% $62,064,160 -$42,895,840 1,892,200 -41% TANG CAPITAL MANAGEMENT, LLC 31 Dec 2025
As of 30 Sep 2026, 212 institutional investors reported holding
69.06MFull value: 69,055,502 · shares · 30 Sep 2026
shares of Spyre Therapeutics, Inc. - Common Stock, $0.0001 par value (SYRE). This represents 68% of the company’s total
101.96MFull value: 101,961,572 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
53%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Paradigm Biocapital Advisors LP 4.4% 4,457,450 7.9% $396,846,774
VANGUARD PORTFOLIO MANAGEMENT LLC 4% 4,063,789 0.02% $361,799,135
VANGUARD CAPITAL MANAGEMENT LLC 3.7% 3,750,793 0.01% $333,933,101
RTW INVESTMENTS, LP 3.6% 3,691,791 3.3% $328,680,153
STATE STREET CORP 3.5% 3,533,862 0.01% $314,608,605
PERCEPTIVE ADVISORS LLC 3.2% 3,280,943 5.5% $292,102,355
Janus Henderson Group Ltd. 2.8% 2,894,015 0.11% $257,756,249
Driehaus Capital Management LLC 2.7% 2,760,448 1.7% $245,762,685
GEODE CAPITAL MANAGEMENT, LLC 2.5% 2,552,798 0.01% $236,412,673
Venrock Adviser, LLC 2.4% 2,485,448 11% $221,279,435
Capital World Investors 2.3% 2,364,029 0.03% $210,469,502
TCG Crossover Management, LLC 1.9% 1,900,582 4.8% $169,208,815
TANG CAPITAL MANAGEMENT LLC 1.9% 1,892,200 7.7% $168,462,566
BANK OF AMERICA CORP /DE/ 1.8% 1,829,875 0.01% $162,913,771
ADAGE CAPITAL PARTNERS GP, L.L.C. 1.7% 1,767,944 0.22% $157,400,054
WELLINGTON MANAGEMENT GROUP LLP 1.5% 1,504,420 0.02% $133,938,513
Affinity Asset Advisors, LLC 1.3% 1,279,134 6.5% $113,881,300
GOLDMAN SACHS GROUP INC 1.2% 1,204,702 0.01% $107,254,628
Remedium Capital Partners, LLC 1.1% 1,160,620 38% $103,329,999
Holocene Advisors, LP 1.1% 1,140,574 0.24% $101,545,303
Polar Capital Holdings Plc 0.97% 985,226 0.25% $87,714,671
WESTFIELD CAPITAL MANAGEMENT CO LP 0.87% 883,904 0.26% $78,693,973
Siren, L.L.C. 0.85% 868,598 1.8% $77,331,280
BRAIDWELL LP 0.7% 713,957 2.6% $63,563,592
Commodore Capital LP 0.69% 700,000 4.8% $62,321,000

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
13
Headline period
Q3 2026
Rows shown
1-13 of 13
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 69,055,502 $6,170,449,278 +$349,330,169 $89.03 212
2026 Q2 95,831,034 $8,518,140,426 +$1,396,540,662 $88.78 264
2026 Q1 82,677,175 $4,164,129,887 +$97,144,106 $50.44 197
2025 Q4 80,976,878 $2,652,563,796 +$541,005,178 $32.76 152
2025 Q3 64,298,657 $1,077,601,900 +$12,200,602 $16.76 136
2025 Q2 63,624,754 $952,552,077 +$19,485,332 $14.97 128
2025 Q1 62,108,053 $1,004,204,799 +$22,237,875 $16.14 128
2024 Q4 59,883,954 $1,394,038,124 +$171,655,898 $23.28 129
2024 Q3 51,375,323 $1,511,815,633 +$36,820,905 $29.41 118
2024 Q2 50,382,939 $1,184,222,119 +$421,575,660 $23.51 106
2024 Q1 31,640,426 $1,196,964,043 +$172,560,163 $37.93 101
2023 Q4 28,010,905 $600,997,673 +$524,495,293 $21.52 54
2023 Q3 3,257,983 $39,909,852 +$39,909,852 $12.25 27
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .